Lahser, F. C., Bystol, K., Curry, S., McMonagle, P., Xia, E., Ingravallo, P., . . . Asante-Appiah, E. (2016). The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother.
Citação norma ChicagoLahser, Frederick C., et al. "The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons." Antimicrob Agents Chemother 2016.
Citação norma MLALahser, Frederick C., et al. "The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons." Antimicrob Agents Chemother 2016.